Ensartinib Market Report 2026

Ensartinib Market Overview

• Ensartinib market size has reached to $1.09 billion in 2025 • Expected to grow to $1.83 billion in 2030 at a compound annual growth rate (CAGR) of 10.9% • Growth Driver: Increase In Lung Cancer Incidence Fueling The Growth Of The Market Due To Rising Air Pollution And Genetic Targeted Therapies • Market Trend: Growing Popularity Of Personal Care Products Fueling The Growth Of The Market Due To Rising Consumer Awareness And Demand For Skin Health Solutions • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Ensartinib Market?

Ensartinib is an oral or injectable targeted cancer therapy that functions as a tyrosine kinase inhibitor, specifically blocking the activity of the anaplastic lymphoma kinase (ALK) protein, which plays a key role in the uncontrolled growth and spread of certain cancer cells. It is mainly prescribed for patients with ALK-positive non-small cell lung cancer, particularly those who have developed resistance or intolerance to earlier-generation ALK inhibitors, helping to slow tumor progression and improve clinical outcomes. The main drug types of ensartinib are oral and injectable. Oral ensartinib refers to the formulation of the drug that is administered by mouth, usually in the form of tablets or capsules. It is used for various patient demographics, such as pediatric patients, adult patients, and geriatric patients, for various indications, such as non-small cell lung cancer (NSCLC), other lung cancers, and potential new indications. It includes treatment lines, such as first-line treatment, second-line treatment, third-line and beyond treatment, and serving end users, such as hospitals, specialty clinics, and others.

What Is The Ensartinib Market Growth Forecast?

The ensartinib market size is expected to see rapid growth in the next few years. It will grow to $1.83 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to expansion of biomarker-driven treatment approaches, increasing approvals for targeted oncology drugs, rising demand for second- and third-line cancer therapies, growing investment in precision medicine research, increasing focus on improving patient survival outcomes. Major trends in the forecast period include increasing adoption of next-generation alk inhibitors, rising focus on precision oncology treatments, growing use of targeted therapy in resistant nsclc cases, expansion of personalized cancer treatment protocols, enhanced clinical monitoring of treatment outcomes.

Global Ensartinib Market Segmentation

1) By Drug Type: Oral, Injectable 2) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients 3) By Indication: Non-Small Cell Lung Cancer (NSCLC), Other Lung Cancers, Potential New Indications 4) By Treatment Line: First-Line Treatment, Second-Line Treatment, Third-Line And Beyond Treatment 5) By End-User: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Oral: Capsules, Tablets, Liquid Formulations, Powder For Oral Suspension 2) By Injectable: Vials, Prefilled Syringes, Lyophilized Powder, Solution For Injection

What Are The Drivers Of The Ensartinib Market?

The increasing incidence of lung cancer is expected to propel the growth of the ensartinib market going forward. Lung cancer refers to a disease in which abnormal cells in the lungs grow uncontrollably, often forming tumors that interfere with normal breathing and may spread to other parts of the body. The incidence of lung cancer is increasing due to prolonged exposure to air pollution, particularly fine particulate matter that damages lung tissue over time. Ensartinib helps treat lung cancer by blocking the abnormal activity of the ALK gene, which helps control tumor growth in patients with ALK-positive non-small cell lung cancer. For instance, in June 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, the number of new cases of lung cancer in United States increased from 218,893 in 2022 to 238,340 in 2023. Therefore, the increasing incidence of lung cancer is driving the growth of the ensartinib industry. The increasing healthcare expenditure is expected to propel the growth of the ensartinib market going forward. Healthcare expenditure refers to the total spending by individuals, organizations, or governments on medical services, public health programs, medications, and other activities aimed at maintaining or improving health. Healthcare expenditure is increasing as the aging population requires more frequent and specialized medical care, leading to higher overall healthcare costs. Healthcare expenditure supports the use of ensartinib by funding access to advanced cancer treatments and enabling their availability in medical facilities. For instance, in April 2025, according to the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, in 2023, health spending in the U.S. rose by 7.5%, reaching $4.9 trillion, or $14,570 per person, marking a notable increase compared to the 4.6% growth observed in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the ensartinib industry.

Key Players In The Global Ensartinib Market

Major companies operating in the ensartinib market are Xcovery Holdings Inc., Betta Pharmaceuticals Co. Ltd.

Global Ensartinib Market Trends and Insights

Major companies operating in the ensartinib market are focusing on obtaining regulatory approvals to broaden patient access across key global markets and secure label expansions that support additional ALK-positive NSCLC indications. Regulatory approvals refer to the formal authorization from health authorities that allow a drug, such as ensartinib, to be marketed and prescribed after proving its safety, efficacy, and quality. For instance, in December 2024, Xcovery Holdings, Inc., a US-based biopharmaceutical company, received FDA approval for ensartinib (marketed as Ensacove) for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor. Approval was based on the phase 3 eXALT3 trial, in which ensartinib showed a significant improvement in progression-free survival compared to crizotinib (median 25.8 vs 12.7 months), though overall survival was similar between groups. Ensartinib is a second-generation ALK inhibitor designed to overcome resistance and target abnormal ALK proteins, with common side effects including rash, muscle pain, constipation, cough, itching, nausea, swelling, fever, and fatigue.

Regional Insights

North America was the largest region in the ensartinib market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ensartinib Market?

The ensartinib market consists of sales of ensartinib capsules, tablets, liquid formulations, prefilled syringes, and lyophilized powder. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ensartinib Market Report 2026?

The ensartinib market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ensartinib industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.